ARCHS4: Massive Mining of Publicly Available RNA Sequencing Data

ARCHS4:大规模挖掘公开的 RNA 测序数据

基本信息

  • 批准号:
    10814654
  • 负责人:
  • 金额:
    $ 15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Summary This supplement project will contribute to the enhancement of the TragetRanger and GeneRanger web-based resources. The work will include: 1) Adding HuBMAP as an additional background atlas for GeneRanger and TargetRanger; 2) Providing the HuBMAP team with feedback about our experience with processing and utilizing the HuBMAP data for incorporation it in GeneRanger and TargetRanger; and 3) Upgrading GeneRanger and TargetRanger box plot visualizations to organize the information in ontological hierarchies that group together cells into tissues, and tissues into organs. The project will be a supplement to the NCI ITCR U24CA264250 grant that was funded to support the advanced development of the widely accessed resource ARCHS4. Data processed from ARCHS4 is already incorporated into GeneRanger and TargetRanger but it is currently not organized into hierarchies. In addition, TargetRanger is mainly useful for discovering novel targets for identifying and removing cancerous cells in tumors. Hence, the incorporation of HuBMAP data as normal tissue background will further strengthen our ability to distill useful targets for the removal of specific cells from tumors while causing minimal damages to normal healthy cells and tissues throughout the human body. Our goal is to make HuBMAP and ARCHS4 data more accessible to researchers while enabling comparisons with other atlasing projects. By processing and incorporating HuBMAP datasets into GeneRanger and TargetRanger resources, we can identify ways to improve the accessibility of HuBMAP data for others seeking to utilize it for analysis, and for adding value to bioinformatics tools and databases. We believe that this knowledge integration effort will enhance the utility of HuBMAP, ARCHS4, as well as GeneRanger and TargetRanger for the research community.
总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Avi Ma'ayan其他文献

Avi Ma'ayan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Avi Ma'ayan', 18)}}的其他基金

The CFDE Workbench
CFDE 工作台
  • 批准号:
    10851224
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
  • 项目类别:
ARCHS4: Massive Mining of Publicly Available RNA Sequencing Data
ARCHS4:大规模挖掘公开的 RNA 测序数据
  • 批准号:
    10693339
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
Proteogenomic translator for cancer biomarker discovery towards precision medicine
用于癌症生物标志物发现和精准医学的蛋白质基因组翻译
  • 批准号:
    10442088
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
ARCHS4: Massive Mining of Publicly Available RNA Sequencing Data
ARCHS4:大规模挖掘公开的 RNA 测序数据
  • 批准号:
    10527721
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
Proteogenomic translator for cancer biomarker discovery towards precision medicine
用于癌症生物标志物发现和精准医学的蛋白质基因组翻译
  • 批准号:
    10655588
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
The LINCS DCIC Engagement Plan with the CFDE
LINCS DCIC 与 CFDE 的合作计划
  • 批准号:
    10837964
  • 财政年份:
    2020
  • 资助金额:
    $ 15万
  • 项目类别:
The LINCS DCIC Engagement Plan with the CFDE
LINCS DCIC 与 CFDE 的合作计划
  • 批准号:
    10468520
  • 财政年份:
    2020
  • 资助金额:
    $ 15万
  • 项目类别:
The LINCS DCIC Engagement Plan with the CFDE
LINCS DCIC 与 CFDE 的合作计划
  • 批准号:
    10444350
  • 财政年份:
    2020
  • 资助金额:
    $ 15万
  • 项目类别:
The LINCS DCIC Engagement Plan with the CFDE
LINCS DCIC 与 CFDE 的合作计划
  • 批准号:
    10682935
  • 财政年份:
    2020
  • 资助金额:
    $ 15万
  • 项目类别:
Knowledge Management Center for Illuminating the Druggable Genome
阐明可药物基因组的知识管理中心
  • 批准号:
    10560469
  • 财政年份:
    2018
  • 资助金额:
    $ 15万
  • 项目类别:

相似海外基金

Development of antibody drug conjugates as pan-filo antivirals
开发作为泛型抗病毒药物的抗体药物偶联物
  • 批准号:
    10759731
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
  • 项目类别:
Proteasome Inhibitor-Loaded Antibody Drug Conjugates with High Drug Loading For Targeted Treatment of Triple Negative Breast Cancers
负载蛋白酶体抑制剂的高载药量抗体药物偶联物用于三阴性乳腺癌的靶向治疗
  • 批准号:
    10822628
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
  • 项目类别:
Next Generation Bio-Orthogonal Ynamine Reagents for the Preparation of Antibody-Drug Conjugates
用于制备抗体-药物缀合物的下一代生物正交胺试剂
  • 批准号:
    2889322
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
  • 项目类别:
    Studentship
Novel antibody-drug conjugates targeting T-cell lymphoma
靶向 T 细胞淋巴瘤的新型抗体-药物偶联物
  • 批准号:
    10386723
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
Targeting breast cancer via site-specific antibody-drug conjugates based on biosynthetically modified enediyne natural products
通过基于生物合成修饰的烯二炔天然产物的位点特异性抗体药物缀合物靶向乳腺癌
  • 批准号:
    514898299
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
    WBP Fellowship
Establishment and validation of the methods for the production of antibody-drug conjugates against malignant skin tumors
抗恶性皮肤肿瘤抗体药物偶联物生产方法的建立和验证
  • 批准号:
    22K16283
  • 财政年份:
    2022
  • 资助金额:
    $ 15万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Developing Novel Bispecific Antibody-Drug Conjugates to Treat Leukaemia
开发新型双特异性抗体药物偶联物来治疗白血病
  • 批准号:
    2600922
  • 财政年份:
    2021
  • 资助金额:
    $ 15万
  • 项目类别:
    Studentship
Project 6- Targeting AML using bispecific and antibody drug conjugates
项目 6 - 使用双特异性和抗体药物偶联物靶向 AML
  • 批准号:
    10615336
  • 财政年份:
    2021
  • 资助金额:
    $ 15万
  • 项目类别:
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
抗体药物偶联物对三阴性乳腺癌的协同靶向治疗
  • 批准号:
    9886056
  • 财政年份:
    2020
  • 资助金额:
    $ 15万
  • 项目类别:
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
抗体药物偶联物对三阴性乳腺癌的协同靶向治疗
  • 批准号:
    10322410
  • 财政年份:
    2020
  • 资助金额:
    $ 15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了